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Not all EGFR mutations are alike and the sensitivity of the less common (“minor”) mutations to epidermal growth fac-
tor receptor (EGFR)-TKIs is often not well defined. Documenting 
sensitivity or resistance of these minor mutations is critical for 
guiding treatment decisions. Here, we use clinical response, in 
vivo evidence of selective pressure, and in silico modeling to 
demonstrate that EGFR S768I sensitizes tumors to erlotinib.
A five pack-year former smoker was diagnosed with 
localized, metachronous lung adenocarcinomas that were 
resected in 2001 and 2003. In 2005, new metastatic lung nod-
ules appeared. Erlotinib 150 mg daily was begun, achieving a 
partial radiographic response (−40% by Response Evaluation 
Criteria in Solid Tumors v1.1, Fig. 1), and then continued for 
8 years with durable response. In 2013, growth in a left upper 
lobe nodule consistent with acquired resistance was detected 
and resected. Mass-spectrometry genotyping of the resistance 
sample revealed EGFR S768I and T790M mutations. The 
original tumors from 2001 and 2003 were also evaluated and 
only the EGFR S768I mutation was detected. Further charac-
terization of the resistance sample with a locked nucleic acid 
probe in the polymerase chain reaction step to completely sup-
press the wild-type allele confirmed that T790M occurred in 
the same clone and in-cis with the S768I mutation (Fig. 2).
We visualized the experimental structure of the EGFR 
protein (Fig. 3). The three-dimensional modeling suggests the 
substitution of serine at position 768 for a bulky isoleucine leads 
to loss of hydrogen bonding between a side chain hydroxyl of 
the original serine and a main chain oxygen of tyrosine at posi-
tion 764. We hypothesize that the disturbance of tightly packed 
residues surrounding this region destabilizes the C-end of the 
alpha-helix (753–768) and pushes the kinase conformational 
equilibrium to favor a constitutively active state.1,2 Notably, the 
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FIGURE 1.  Radiographic response 
to erlotinib in patient with 
EGFR S768I mutation (−40% by 
Response Evaluation Criteria in 
Solid Tumors v1.1).
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location of S768 is outside the erlotinib binding pocket, which 
would assert no immediate steric hinderance to erlotinib binding 
and is consistent with the sensitivity to erlotinib seen in vivo.
The EGFR S768I point mutation occurs in 1–2% of 
EGFR mutant lung cancers.3 In vitro studies demonstrate 
the transforming capacity of this mutation.4 However, sensi-
tivity to EGFR-TKIs has been controversial; in vitro studies 
reported relative resistance,4 whereas one prior clinical case of 
an EGFR S768I mutant lung adenocarcinoma reported appar-
ent sensitivity to gefitinib.5 However, it was unknown if the 
responding tumors were distinct subclones with a different or 
additional EGFR mutation. In other previously reported cases, 
EGFR S768I is often coincident with other EGFR mutations, 
which has further limited conclusions.
This case provides conclusive evidence that EGFR 
S768I mutant lung adenocarcinomas are sensitive to erlo-
tinib. The in vivo emergence of EGFR T790M in the same 
allele confirms the selective pressure of erlotinib on the EGFR 
S768I mutant kinase. We believe molecular analyses of lung 
adenocarcinomas should evaluate for EGFR S768I mutations 
and patients harboring this mutation should receive an EGFR-
tyrosine kinase inhibitor as initial therapy.
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FIGURE 2.  Mutation analysis of exon 
20 of EGFR in the tumor sample using 
standard sequencing. A, Electropherogram 
from tumor before EGFR-tyrosine kinase 
inhibitor shows the mutation S768I and 
absence of T790M. (B) Electropherogram 
from tumor at acquired resistance shows 
both S768I and T790M. Both the wild-
type and the mutant alleles are present. 
(C) Electropherogram corresponds to 
sequencing after LNA-polymerase chain 
reaction with a probe targeting the wild-
type sequence in the region encompassing 
codons 789–792. With suppression of the 
wild-type allele, only the mutant peaks for 
S768I and T790M are present, indicating 
mutations are in-cis (same allele).
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FIGURE 3.  Three-dimensional structure of the EGFR kinase 
domain illustrating the location of the EGFR S768I and the 
T790M mutations (Protein Data Bank code of EGFR structure 
used is 1m17). The substitution of serine for a bulky isoleu-
cine at position 768 will result in a loss of hydrogen bonding 
between a side chain hydroxyl of Ser768 and a main chain 
oxygen of Tyr764 (circled in red). The loss of the hydrogen 
bond and the disturbance of the tight residue packing in the 
mutation position is predicted to destabilize the C-end of 
the alpha-helix (753–768). We hypothesize that the confor-
mational changes at the C-end of the alpha-helix will lead to 
an equilibrium shift favoring an active conformation of the 
kinase. Importantly, the location of this change is outside 
the binding pocket of erlotinib (green), thereby permitting 
binding of erlotinib in this pocket. By contrast, the substitu-
tion of a small threonine residue for a bulky methionine in 
the T790M mutation, directly affects the drug binding pocket 
rendering the protein resistant to the drug.
